GlaxoSmithKline Pharmaceuticals shares fall 2.01%; among top losers on Nifty Midcap 150

Disclaimer This is an AI-assisted live blog with updates from multiple sources Disclaimer

Shares of GlaxoSmithKline Pharmaceuticals declined by 2.01% to Rs 3,081 at 3:13 pm on Monday. The stock is among the top losers on the Nifty Midcap 150 index. The decline reflects a shift in investor sentiment, as the stock faced selling pressure during today's session.

Financial Snapshot:

GlaxoSmithKline Pharmaceuticals' financial performance shows a consistent trend in revenue and profit growth. Here's a look at the company's consolidated quarterly and annual results:

Consolidated Quarterly Results (Rs. Crore)

The quarterly revenue has shown fluctuations, with a high of Rs 1,010.77 Crore in September 2024 and a recent value of Rs 974.37 Crore in March 2025. Net profit also reflects this trend, peaking at Rs 262.87 Crore in March 2025.

Consolidated Yearly Results (Rs. Crore)

The annual revenue has consistently increased from Rs 2,925.60 Crore in 2021 to Rs 3,749.21 Crore in 2025. The net profit also shows a positive trend, with a significant increase to Rs 927.58 Crore in 2025. The Debt to Equity ratio has remained at 0.00 over the years, indicating a debt-free status.

Consolidated Yearly Income Statement (Rs. Crore)

The sales has increased by 8.57% in 2025 compared to 2024. The net profit has increased by 57.38% in 2025 compared to 2024.

Consolidated Quarterly Income Statement (Rs. Crore)

The sales for Mar 2025 quarter is Rs 974 Crore, which is an increase of 4.84% compared to Mar 2024 quarter. The net profit for Mar 2025 quarter is Rs 262 Crore, which is an increase of 35.05% compared to Mar 2024 quarter.

Cash Flow (Rs. Crore)

Balance Sheet (Rs. Crore)

Financial Ratios

Corporate Actions

GlaxoSmithKline Pharmaceuticals has announced several corporate actions, including dividends and bonus issues. Recent announcements include:

• Dividends: The company announced a final dividend of Rs 42 per share (420%) on May 13, 2025, with an effective date of May 30, 2025. Prior dividends include an interim dividend of Rs 12 per share (120%) announced on October 24, 2024, and a final dividend of Rs 32 per share (320%) announced on May 17, 2024.
• Bonus Issues: The company has a history of bonus issues, including a 1:1 bonus ratio announced on July 24, 2018, with an ex-bonus date of September 11, 2018.
• Rights Issues: A rights issue was announced on September 30, 1993, with a ratio of 1:5 and a premium of Rs 55.

Additional announcements include newspaper publications, compliance certificates, and changes in management, as per disclosures to the stock exchanges.

Moneycontrol's sentiment analysis, as of July 24, 2025, indicates a neutral outlook on the stock.

With the stock's last traded price at Rs 3,081, GlaxoSmithKline Pharmaceuticals has experienced a notable decline, positioning it among the top losers on the Nifty Midcap 150 index.